Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program.
Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program.
复制标题
重组人类生长激素（而非胰岛素样生长因子-I）可增强接受节食和锻炼计划的绝经后妇女的中心脂肪减少。
DOI：
10.1055/s-2001-14930
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
Marcus,R
中科院分区：
文献类型：
--
作者：
Taaffe,DR;Thompson,JL;Butterfield,GE;Hoffman,AR;Marcus,R
我们研究了重组人生长激素（rhGH）和/或重组人胰岛素样生长因子-I（rhIGF-I）对接受饮食加运动减肥方案的绝经后妇女局部脂肪减少的影响。27名年龄在59-79岁的女性，比理想体重高出20-40%，完成了为期12周的计划，包括每周2天的阻力训练和每周3天的步行，同时消耗的饮食比维持体重所需的饮食少500千卡/天。参与者以双盲方式随机分配接受rhGH（0.025 mg/kg BW/天; n= 7），rhIGF-I（0.015 mg/kg BW/天; n= 7），rhGH+ rhIGF-I（n= 6）或安慰剂（PL; n= 7）。双能X线吸收法测定局部和全身脂肪量。通过躯干脂肪/肢体脂肪（TrF/LimbF）和躯干脂肪/总脂肪（TrF/TotF）的比值评估体脂分布。四肢和躯干脂肪减少（P< 0.01）。对于两种脂肪分布比率，与外周脂肪相比，rhGH给药组的躯干损失增加（p≤ 0.01），而rhIGF-I或PL给药组无显著变化。脂肪分布的变化与心血管疾病风险指数（由血脂/脂蛋白水平和最大有氧能力确定）之间没有关联。这些结果表明，rhGH的管理有利于减少中央相比，外周脂肪的老年妇女进行减肥计划，结合运动和适度的热量限制，虽然没有有利的影响，赋予脂质/脂蛋白谱。此外，rhGH与rhIGF-I联合给药不会增强rhGH的作用。此外，单独给药时，rhIGF-I不会增加躯干脂肪的损失。
We examined the effect of recombinant human growth hormone (rhGH) and/or recombinant human insulin-like growth factor-I (rhIGF-I) on regional fat loss in postmenopausal women undergoing a weight loss regimen of diet plus exercise. Twenty-seven women aged 59-79 years, 20-40% above ideal body weight, completed a 12-week program consisting of resistance training 2 days/week and walking 3 days/week, while consuming a diet that was 500 kcal/day less than that required for weight maintenance. Participants were randomly assigned in a double-blind fashion to receive rhGH (0.025 mg/kg BW/day; n= 7), rhIGF-I (0.015 mg/kg BW/day; n= 7), rhGH+ rhIGF-I (n= 6), or placebo (PL; n= 7). Regional and whole body fat mass were determined by dual X-ray absorptiometry. Body fat distribution was assessed by the ratios of trunk fat-to-limb fat (TrF/LimbF) and trunk fat-to-total fat (TrF/TotF). Limb and trunk fat decreased in all groups (p< 0.01). For both ratios of fat distribution, the rhGH treated group experienced an enhanced loss of truncal compared to peripheral fat (p≤ 0.01), with no significant change for those administered rhIGF-I or PL. There was no association between change in fat distribution and indices of cardiovascular disease risk as determined by serum lipid/lipoprotein levels and maximal aerobic capacity. These results suggest that administration of rhGH facilitates a decrease in central compared to peripheral fat in older women undertaking a weight loss program that combines exercise and moderate caloric restriction, although no beneficial effects are conferred to lipid/lipoprotein profiles. Further, the effect of rhGH is not enhanced by combining rhGH with rhIGF-I administration. In addition, rhIGF-I does not augment the loss of trunk fat when administered alone.